Professional
Added to YB: 2024-09-10
Pitch date: 2024-09-10
AADI [neutral]
Whitehawk Therapeutics, Inc.
+141.57%
current return
Author Info
Special Situation Investments focuses on event-driven trades and low risk arbitrage opportunities with short term catalysts. Sign up for the newsletter.
Company Info
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
Market Cap
$194.7M
Pitch Price
$1.78
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.58
P/E
-2.36
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Aadi Bioscience: Worth Watching Amid Strategic Review and Net Cash Play
AADI (high uncertainly, but watching closely): Busted biopharma trading 10% below net cash. Failed Phase 2, 80% R&D layoffs. Commercialized PEComa drug (100-300 patients, $25M sales) up for sale. Strategic review ongoing. 40% insider ownership. Drug value est. 1-1.5x sales. $9M est. quarterly cash burn.
Read full article (2 min)